^
Association details:
| Biomarker: | MCL1 underexpression |
|---|---|
| Cancer: | T Acute Lymphoblastic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + volasertib (NBL-001) (PLK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action
Published date:
11/06/2019
Excerpt:
A higher degree of apoptosis was also observed in the combination treatment as compared to a single drug. Immunoblot analysis revealed cleavage of PARP1 and lower levels of c-Myc and MCL1 expression in the presence of both ABT-199 and BI-6727.
DOI:
https://doi.org/10.1182/blood-2019-129823
